张丽娥 张岁龙△ 魏凤英 封晓荣 张倩蓉.缬沙坦联合氨氯地平治疗高血压伴左心肥厚的疗效及对心功能的影响[J].现代生物医学进展英文版,2016,16(9):1684-1686. |
缬沙坦联合氨氯地平治疗高血压伴左心肥厚的疗效及对心功能的影响 |
Valsartan plus Amlodipine for Hypertension Complicated by Left VentricularHypertrophy: Its Clinical Efficacy and Influence on Heart Function |
|
DOI: |
中文关键词: 高血压 左心肥厚 缬沙坦 氨氯地平 |
英文关键词: Hypertension Left ventricular hypertrophy Valsartan Amlodipine |
基金项目: |
|
Hits: 1136 |
Download times: 0 |
中文摘要: |
目的:通过探讨缬沙坦联合氨氯地平治疗高血压伴左心肥厚患者的疗效及对心功能的影响,为临床治疗提供依据。方法:选
择2010 年1 月~2014 年12 月我院收治的高血压伴左心室肥厚患者共120 例,按照随机数字表法随机分为观察组和对照组。对
照组患者给予氨氯地平,观察组患者缬沙坦联合氨氯地平治疗,治疗6 个月后,观察两组患者舒张压(DBP)、收缩压(SBP)、心率
(HR)、室间隔厚度(IVST),左室后壁厚度(LVPWT)、左室舒张末期内径(LVDd)和左室重量指数(LVMI)。结果:治疗后,两组患者
SBP、DBP 和HR均较治疗前显著降低,差异有统计学意义(P<0.05);观察组患者SBP、DBP和HR均低于对照组,差异有统计学意
义(P<0.05)。治疗后,两组患者IVST、IVPWT、LVDd 和LVMI 均较治疗前显著降低,差异有统计学意义(P<0.05);观察组患者
IVST、IVPWT、LVDd 和LVMI均低于对照组,差异有统计学意义(P<0.05)。结论:缬沙坦联合氨氯地平治疗高血压伴左心肥厚患
者,能够降低患者血压、逆转左心室肥厚,改善患者心功能,疗效优于氨氯地平单独治疗,值得临床推广应用。 |
英文摘要: |
Objective:To explore the clinical efficacy and the influence on heart function of valsartan plus amlodipine in the treatment
of hypertension complicated by left ventricular hypertrophy,and to provide the reference for clinical therapy.Methods:A total of
120 patients with hypertension complicated by left ventricular hypertrophy, who were admitted to Second Affiliated Hospital of Xi'an
Jiao Tong University from January 2010 to December 2014, were selected and randomly divided into observation group and control
group. The control group was treated with amlodipine, while the observation group was treated with valsartan plus amlodipine. After 6
months of treatment, the diastolic blood pressure(DBP), systolic blood pressure(SBP), heart rate (HR), interventricular septal thickness
(IVST), left ventricular posterior wall thickness(LVPWT), left ventricular end diastolic diameter(LVDd), and left ventricular mass index
(LVMI) in the two groups were observed.Results:Compared with before treatment, SBP, DBP, and HR in the two groups after treatment
were significantly reduced, the differences were statistically significant (P<0.05); and the above indexes in the observation group were
lower than those in the control group, the differences were statistically significant (P<0.05); IVST, IVPWT, LVDd and LVMI in the two
groups after treatment were significantly reduced, the differences were statistically significant (P<0.05), and the above indexes in the observation
group were lower than those in the control group, the differences were statistically significant (P<0.05).Conclusion:Valsartan
plus amlodipine can significantly cut down the blood pressure, reverse left ventricular hypertrophy and improve the heart function in the
treatment of patients with hypertension complicated by left ventricular hypertrophy, its clinical efficacy is better than amlodipine alone,
which is worthy of clinical popularization and application. |
View Full Text
View/Add Comment Download reader |
Close |
|
|
|